Zentalis Pharmaceuticals, Inc. (ZNTL) Key Metrics
ZNTL valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $209.0M
- Enterprise value
- $130.7M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 7.1
- Price / book
- 1.9 10-yr median 2.4
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.94
ZNTL key metrics, 2018–2025
Fiscal year ended December 31, 2025 · U.S. dollarsZNTL valuation Price multiples at each fiscal year-end price.
ZNTL returns How much profit the business earns on the capital it uses.
ZNTL per-share figures Results divided by the shares outstanding at year-end.
ZNTL financial health Debt, liquidity and how easily interest is covered.
ZNTL efficiency & capital use Working capital cycle and where the cash goes.
ZNTL valuation history
ZNTL returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ZNTL debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ZNTL cash returned to shareholders
ZNTL price vs earnings per share
ZNTL key metrics
2018–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||
| Market capitalization | $97.0M | $215.4M | $990.9M | $1.06B | $3.59B | $2.13B | — | — |
| Enterprise value | −$109.3M | −$113.1M | $553.8M | $674.5M | $3.29B | $1.80B | — | — |
| Price / sales | — | 3.2 | — | — | — | — | — | — |
| Price / book | 0.4 | 0.6 | 2.3 | 2.5 | 9.9 | 6.9 | — | — |
| EV / sales | — | -1.7 | — | — | — | — | — | — |
| Earnings yield | −141.3% | −77.0% | −29.5% | −22.2% | −4.4% | −5.5% | — | — |
| Free cash flow yield | −129.1% | −79.4% | −21.0% | −15.6% | −4.5% | −4.1% | — | — |
| Shareholder yield (dividends + buybacks) | 10.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Share price at fiscal year-end | $1.35 | $3.03 | $15.15 | $20.14 | $84.06 | $51.94 | — | — |
| Per share | ||||||||
| Revenue per share | $0.00 | $0.95 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Earnings per share | −$1.91 | −$2.33 | −$4.47 | −$4.48 | −$3.72 | −$2.87 | −$1.27 | — |
| Operating cash flow per share | −$1.74 | −$2.40 | −$3.18 | −$3.10 | −$3.61 | −$2.12 | −$1.09 | — |
| Free cash flow per share | −$1.74 | −$2.41 | −$3.19 | −$3.15 | −$3.75 | −$2.13 | −$1.10 | — |
| Cash per share | $3.42 | $5.22 | $7.38 | $8.27 | $7.97 | $8.25 | $1.87 | — |
| Book value per share | $3.01 | $4.74 | $6.69 | $8.21 | $8.53 | $7.52 | $1.72 | — |
| Tangible book value per share | $3.01 | $4.74 | $6.63 | $8.14 | $8.44 | $7.21 | $1.37 | — |
| Capex per share | $0.00 | $0.00 | $0.01 | $0.05 | $0.14 | $0.02 | $0.01 | — |
| Debt per share | $0.55 | $0.60 | $0.70 | $0.90 | $1.08 | $0.05 | $0.07 | — |
| Shares outstanding | 71.9M | 71.1M | 65.4M | 52.9M | 42.7M | 41.0M | 35.9M | — |
| Change in shares outstanding | +1.1% | +8.7% | +23.7% | +23.8% | +4.0% | +14.4% | — | — |
| Returns & profitability | ||||||||
| Return on equity (ROE) | −49.5% | −42.8% | −67.1% | −59.4% | −47.2% | −63.7% | −105.7% | −85.1% |
| Return on invested capital (ROIC) | — | — | — | −316.4% | −818.3% | — | — | — |
| Return on assets (ROA) | −38.1% | −33.4% | −52.4% | −46.2% | −37.9% | −51.9% | −70.7% | −51.4% |
| Return on tangible assets | −47.4% | −38.5% | −52.3% | −43.1% | −33.9% | −33.4% | −60.3% | −74.0% |
| Free cash flow margin | — | −253.7% | — | — | — | — | — | — |
| Financial health | ||||||||
| Total debt | $39.6M | $42.6M | $45.8M | $47.3M | $45.9M | $2.0M | $2.5M | — |
| Cash & short-term investments | $245.9M | $371.1M | $482.9M | $437.4M | $340.1M | $338.5M | $67.2M | $25.2M |
| Net debt | −$206.3M | −$328.4M | −$437.1M | −$390.0M | −$294.2M | −$336.5M | −$64.8M | −$25.2M |
| Debt / equity | 0.18 | 0.13 | 0.10 | 0.11 | 0.13 | 0.01 | 0.04 | — |
| Debt / assets | 0.14 | 0.10 | 0.08 | 0.09 | 0.10 | 0.01 | 0.03 | — |
| Current ratio | 6.93 | 7.32 | 7.16 | 7.98 | 7.98 | 12.07 | 4.62 | 4.30 |
| Quick ratio | 6.93 | 7.32 | 7.16 | 8.10 | 8.08 | 12.07 | 4.62 | 4.30 |
| Interest coverage | — | — | — | -88.3 | -2.0 | -53.2 | -39.1 | — |
| Working capital | $216.6M | $333.3M | $427.4M | $395.3M | $306.8M | $316.5M | $54.0M | $20.5M |
| Invested capital | $9.9M | $8.8M | $138,000 | $43.8M | $69.7M | −$27.9M | −$3.2M | −$384,000 |
| Tangible asset value | $216.2M | $337.2M | $433.7M | $430.3M | $360.7M | $320.8M | $55.9M | $19.8M |
| Net current asset value | $180.4M | $292.9M | $372.1M | $332.5M | $243.2M | $312.9M | $49.1M | $18.0M |
| Graham net-net per share | $2.43 | $3.96 | $5.48 | $6.05 | $5.44 | $7.47 | $1.33 | — |
| Capital allocation | ||||||||
| Share buybacks (net) | $10.0M | $0 | $0 | $0 | $1,146 | $0 | $0 | $0 |
| Capex / revenue | — | 0.3% | — | — | — | — | — | 1,621.4% |
| Capex / depreciation | 0.00 | 0.17 | 0.42 | 1.79 | 11.23 | 4.74 | 3.17 | 4.45 |
| Stock-based compensation / revenue | — | 99.8% | — | — | — | — | — | 2,200.0% |
| R&D / revenue | — | 248.8% | — | — | — | — | — | 135,150.0% |
| SG&A / revenue | — | 129.2% | — | — | — | — | — | 34,828.6% |
| Efficiency | ||||||||
| Days sales outstanding | — | 27.1 | — | — | — | — | — | 23,907.5 |
| Days of inventory on hand | — | — | — | -1,469.2 | -2,978.4 | — | — | — |
| Days payables outstanding | 3,616.9 | 3,166.4 | 3,438.9 | 2,922.7 | 6,793.8 | 14,771.1 | 12,692.8 | — |
| Cash conversion cycle (days) | — | -3,139.3 | — | — | — | — | — | — |
| Receivables turnover | 0.00 | 13.48 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 |
| Payables turnover | 0.10 | 0.12 | 0.11 | 0.12 | 0.05 | 0.02 | 0.03 | 0.00 |
| Asset turnover | 0.00 | 0.14 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | $3.5M | $5.0M | — | $4.8M | $1.5M | $278,500 | $528,500 | $917,000 |
| Average payables | $7.3M | $11.2M | $13.1M | $11.4M | $10.1M | $6.5M | $3.9M | $3.4M |
| Average inventory | — | — | — | −$5.7M | −$4.4M | — | — | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.7% | 0.7% | 0.8% | 3.4% | 14.2% | 30.6% |
Computed from ZNTL's annual financial statements (latest annual report filed March 26, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
ZNTL valuation and financial ratios
Zentalis Pharmaceuticals earned a return on equity of −49.5% in fiscal 2025. It ended the year with $39.6 million of debt and $245.9 million in cash and short-term investments, a net cash position of $206.3 million. It returned $10.0 million to shareholders: $0 in dividends and $10.0 million in share buybacks.
See the ZNTL income statement, the ZNTL chart for price history, or the ZNTL stock overview for the latest quote and news.
ZNTL key metrics FAQ
What is Zentalis Pharmaceuticals's return on equity?
Zentalis Pharmaceuticals's return on equity (ROE) was −49.5% in fiscal 2025: net income of -$137.1 million on average shareholders' equity of $276.7 million.
How much debt does Zentalis Pharmaceuticals have?
Zentalis Pharmaceuticals had total debt of $39.6 million at the end of fiscal 2025, a debt-to-equity ratio of 0.18 and more cash than debt.
Does Zentalis Pharmaceuticals buy back its shares?
Yes. Zentalis Pharmaceuticals spent $10.0 million on net share repurchases in fiscal 2025 Shares outstanding changed +1.1% over the year, to 71.9M..
What is Zentalis Pharmaceuticals's free cash flow yield?
Zentalis Pharmaceuticals generated -$125.2 million of free cash flow in fiscal 2025, a free cash flow yield of −129.1% on its market value at year-end ($97.0 million).
What is Zentalis Pharmaceuticals's current ratio?
Zentalis Pharmaceuticals's current ratio was 6.93 at the end of fiscal 2025: current assets were 6.93 times current liabilities.